Pharmaceuticals
Reimagining Piramal: Blood, sweat, but no tears
An old Indian business house still has fire in its belly(1)
Drugmakers and antibiotics: The path of least resistance
Governments reckon that drug firms’ research efforts need a shot in the arm(9)
Drug research: All together now
Charities help Big Pharma(2)
The drugs industry: Battling borderless bugs
Western and emerging-market drug firms are invading each other’s turf(20)
Big Pharma struggles to protect its blockbusters as they lose patent protection(11)
Pharmaceutical firms: Let's split
A big health-care company splits in two(11)
Cancer drugs: Big Pharma's gripes about the FDA
Genentech's battle with the regulator over Avastin, an expensive cancer treatment, will be the first of many(13)
Where pharmacuetical firms are concentrating their efforts(12)
Drug companies in America: The costly war on cancer
New cancer drugs are technically impressive. But must they cost so much?(37)
Barack Obama and business: Forest firing
The government seeks to sack an innocent boss(8)
Resistance to antibiotics: The spread of superbugs
What can be done about the rising risk of antibiotic resistance?(29)
Jeffrey Kindler, Pfizer's boss abruptly resigns, saying he can't take the pressure from disappointed investors(11)
Business: Research and develop
Andrew Witty, CEO of GlaxoSmithKline, calls on the pharmaceutical industry to do more with less—and still be innovative(1)
Pharmaceuticals: Attack of the biosimilars
Biotechnology drugs are the next target for cheaper versions(5)
Sanofi and Genzyme: Fighting over orphans
The trouble with Sanofi's bid for Genzyme(2)
Japan's drug firms on the move: A homespun elixir
With growth limited at home, Japan’s pharma industry is buying firms abroad(2)
Pills get smart: Potential encapsulated
Medicines that can talk to doctors herald a new direction for drugs firms(7)
Novartis's bid for Alcon: In the eye
Minority shareholders in Swiss firms have fewer rights than they thought(4)
Expiring patents are a bitter pill for drug companies(12)
Roche digests Genentech: Back to the lab
The newly expanded pharmaceutical firm bets on old-fashioned research(2)
Business: Generically challenged
The pharmaceuticals industry may yet find inspiration in its old nemesis, the generic-drugs business(0)
Drug firms buy vaccine-makers: Shot in the dark
Pharmaceutical giants may regret their stampede into the vaccine business(4)
Advertisement
Most commented
- Foreigners in China: Barbarians at the gate, again
- The euro crisis: The Greek run
- The future of the European Union: The choice
- Politics and private equity: Bringing the Bain
- Russia and NATO: Rethink the reset
- Brazil’s economy: A bull diminished
- India-China relations and the media: Blame the messenger
- Gay marriage: North Carolina begs the question too
- Nationalism online: Backfired
- Barack and Bain: A president's background training matters
Over the past five days
Most recommended
- Foreigners in China: Barbarians at the gate, again
- The euro crisis: The Greek run
- Jacob Zuma: Portrait of a president
- Brazil’s economy: A bull diminished
- Facebook goes public: Not top of the pops
- Obesity: Difference Engine: Food for thought
- Names in translation: Another cock-up
- Politics and private equity: Bringing the Bain
- Daily chart: Good news from Africa
- The future of the European Union: The choice
Over the past seven days
Advertisement
